Senna-s

Docusate Sodium And Sennosides


Walgreens
Human Otc Drug
NDC 0363-3010
Senna-s also known as Docusate Sodium And Sennosides is a human otc drug labeled by 'Walgreens'. National Drug Code (NDC) number for Senna-s is 0363-3010. This drug is available in dosage form of Capsule, Gelatin Coated. The names of the active, medicinal ingredients in Senna-s drug includes Docusate Sodium - 50 mg/1 Sennosides - 8.6 mg/1 . The currest status of Senna-s drug is Active.

Drug Information:

Drug NDC: 0363-3010
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Senna-s
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Docusate Sodium And Sennosides
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Walgreens
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Capsule, Gelatin Coated
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DOCUSATE SODIUM - 50 mg/1
SENNOSIDES - 8.6 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Mar, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 15 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part334
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Walgreens
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1791612
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0311917183251
UPC stands for Universal Product Code.
UNII:F05Q2T2JA0
3FYP5M0IJX
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0363-3010-601 BOTTLE, PLASTIC in 1 CARTON (0363-3010-60) / 60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC03 Jul, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Active ingredients (in each softgel) purpose docusate sodium 50 mg stool softener sennosides 8.6 mg laxative

Product Elements:

Senna-s docusate sodium and sennosides fd&c yellow no. 6 gelatin glycerin polyethylene glycol 400 povidone k30 propylene glycol water sorbitol titanium dioxide docusate sodium docusate sennosides sennosides opaque softgel s62

Indications and Usage:

Uses relieves occasional constipation (irregularity) generally produces bowel movement in 6-12 hours

Warnings:

Warnings do not use if you are now taking mineral oil, unless directed by a doctor laxative products for longer than 1 week, unless directed by a doctor ask a doctor before use if you have stomach pain nausea vomiting noticed a sudden change in bowel habits that lasts over 2 weeks stop use and ask a doctor if you have rectal bleeding or fail to have a bowel movement after use of a laxative. these may indicate a serious condition. if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away.

Do Not Use:

Warnings do not use if you are now taking mineral oil, unless directed by a doctor laxative products for longer than 1 week, unless directed by a doctor ask a doctor before use if you have stomach pain nausea vomiting noticed a sudden change in bowel habits that lasts over 2 weeks stop use and ask a doctor if you have rectal bleeding or fail to have a bowel movement after use of a laxative. these may indicate a serious condition. if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away.

Dosage and Administration:

Directions take preferably at bedtime or as directed by a doctor age starting dosage maximum dosage adults and children 12 years of age or older 2 softgels once a day 4 softgels twice a day children 6 to under 12 years 1 softgel once a day 2 softgels twice a day children 6 years and under ask a doctor ask a doctor

Stop Use:

Stop use and ask a doctor if you have rectal bleeding or fail to have a bowel movement after use of a laxative. these may indicate a serious condition.

Package Label Principal Display Panel:

Principal display panel - 60 softgels bottle carton walgreens compare to senokot-s® active ingredients†† ndc 0363-3010-60 senna-s docusate sodium 50 mg / stool softener sennosides 8.6 mg / laxative softgels dual action • gently relieves constipation • stool softener 60 softgels actual size image description

Further Questions:

Questions? call 1-888-333-9792 monday-friday 9am-5pm est


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.